Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program
Minghui, a Chinese biotech company, has raised $131 million in a 'pre-IPO' financing round235.
The funding will be used to advance the company's PD-1xVEGF bispecific antibody program, as well as support the launch of its JAK inhibitor and additional antibody-drug conjugate (ADC) clinical trials235.
The round positions Minghui to accelerate development of oncology therapies, underscoring ongoing investor interest in novel immuno-oncology assets emerging from China5.
The PD-1xVEGF bispecific antibody targets both PD-1 and VEGF pathways, which are relevant for cancer immunotherapy and anti-angiogenesis strategies, aiming to improve outcomes in solid tumors5.
Sources:
2. https://ftp.fiercedrugsafety.com/biotech/tapimmune-to-merge-baylor-adoptive-t-cell-startup-marker